wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
Company profile
Ticker
WVE
Exchange
Website
CEO
Paul Bolno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Wave Life Sciences Pte Ltd
SEC CIK
WVE stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
6 Mar 24
8-K
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
6 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
4 Jan 24
8-K
Regulation FD Disclosure
15 Dec 23
424B5
Prospectus supplement for primary offering
8 Dec 23
8-K
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
7 Dec 23
424B5
Prospectus supplement for primary offering
6 Dec 23
8-K
Regulation FD Disclosure
9 Nov 23
S-8
Registration of securities for employees
9 Nov 23
Transcripts
WVE
Earnings call transcript
2023 Q4
6 Mar 24
WVE
Earnings call transcript
2023 Q3
9 Nov 23
WVE
Earnings call transcript
2023 Q2
3 Aug 23
WVE
Earnings call transcript
2023 Q1
3 May 23
WVE
Earnings call transcript
2022 Q4
22 Mar 23
WVE
Earnings call transcript
2022 Q3
10 Nov 22
WVE
Earnings call transcript
2022 Q2
11 Aug 22
WVE
Earnings call transcript
2022 Q1
12 May 22
WVE
Earnings call transcript
2021 Q4
3 Mar 22
WVE
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
Kyle Moran
5 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
SC 13G/A
MAVERICK CAPITAL LTD
14 Feb 24
SC 13G/A
683 Capital Management, LLC
14 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
M28 Capital Management LP
12 Feb 24
4
Chris Francis
7 Feb 24
4
PAUL BOLNO
7 Feb 24
4
Kyle Moran
7 Feb 24
4
Chandra Vargeese
7 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 139.94 mm | 139.94 mm | 139.94 mm | 139.94 mm | 139.94 mm | 139.94 mm |
Cash burn (monthly) | 11.01 mm | (no burn) | (no burn) | 7.56 mm | 11.49 mm | 1.64 mm |
Cash used (since last report) | 74.69 mm | n/a | n/a | 51.30 mm | 77.91 mm | 11.10 mm |
Cash remaining | 65.25 mm | n/a | n/a | 88.64 mm | 62.03 mm | 128.84 mm |
Runway (months of cash) | 5.9 | n/a | n/a | 11.7 | 5.4 | 78.8 |
Institutional ownership, Q2 2023
82.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 86 |
Opened positions | 27 |
Closed positions | 17 |
Increased positions | 21 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 251.52 bn |
Total shares | 101.40 mm |
Total puts | 12.70 k |
Total calls | 25.90 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 17.20 mm | $62.62 bn |
GSK GSK | 10.68 mm | $50.32 mm |
Shin Nippon Biomedical Laboratories | 9.61 mm | $18.35 mm |
M28 Capital Management | 7.05 mm | $25.66 bn |
Maverick Capital | 6.60 mm | $24.01 bn |
683 Capital Management | 6.03 mm | $21.95 bn |
BLK Blackrock | 4.62 mm | $16.83 bn |
Adage Capital Partners GP, L.L.C. | 4.62 mm | $16.81 bn |
BBBOF BB Biotech | 4.49 mm | $0.00 |
BLVGF Bellevue | 4.49 mm | $16.36 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Kyle Moran | Ordinary Shares | Sell | Dispose S | No | Yes | 6.169 | 15,630 | 96.42 k | 33,921 |
5 Feb 24 | Chandra Vargeese | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.87 | 361,700 | 1.40 mm | 361,700 |
5 Feb 24 | Paul Bolno | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.87 | 1,008,600 | 3.90 mm | 1,008,600 |
5 Feb 24 | Chris Francis | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.87 | 286,400 | 1.11 mm | 286,400 |
5 Feb 24 | Kyle Moran | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.87 | 371,500 | 1.44 mm | 371,500 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Apr 24
Truist Securities Reiterates Buy on WAVE Life Sciences, Maintains $17 Price Target
1 Apr 24
Mizuho Maintains Buy on WAVE Life Sciences, Raises Price Target to $19
12 Mar 24
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
7 Mar 24
American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday
7 Mar 24